Highlights of the Annual Press Conference 2011
Video with highlights of the Annual Press Conference on 05 April 2011.
Annual Press Conference 2011
Boehringer Ingelheim presented results of the business development 2010 and outlook for 2011 at the Annual Press Conference, 05 April 2011, in the Boehringer Ingelheim Centre in Ingelheim.
Annual Report Website
Annual Report 2010
Annual Press Conference 2011
In the business year 2010, Boehringer Ingelheim almost compensated for the anticipated loss of turnover announced in advance last year, nearly achieving the previous year‘s level. For 2011, Boehringer Ingelheim expects robust overall growth.
News Release
05.04.2011 - Boehringer Ingelheim maintains sales level / course set for the future: product pipeline well-filled. More ...
05.04.2011- Boehringer Ingelheim hält Umsatzniveau / Weichen für die Zukunft gestellt: Produkt-Pipeline gut gefüllt . Mehr ...
-
Prof. Dr Dr Andreas Barner
Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Research, Development and Medicine.
Prof. Dr Dr Barner presents the business development 2010 and business perspective 2011 and gives an overview about the Research & Development pipeline.
-
Videos
-
-
Webcast on Demand
Video taken during the Annual Press Conference on 05 April 2011.
-
-
Images from the Annual Press Conference 2011
-
Annual Press Conference Impression
Arrival of journalists at the Annual Press Conference registration office at Boehringer Ingelheim in Ingelheim, Germany.
-
Annual Press Conference Impression
Arrival of the participants attending the Annual Press Conference 2011 at Boehringer Ingelheim in Ingelheim, Germany.
-
Annual Press Conference Impression
Prof. Dr Dr Andreas Barner, Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Research, Development and Medicine, in a discussion with journalists from Asia.
-
Annual Press Conference Impression
Participants of the Annual Press Conference 2011
-
Annual Press Conference Impression
Prof. Dr Dr Andreas Barner, Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Research, Development and Medicine answering a question from a journalist.
-
Annual Press Conference Impression
Photo shooting at the Annual Press Conference in Ingelheim
-
-
Images - Board Members; Chairman of the Shareholders' Committee
Board of Managing Directors
-
Prof. Dr Dr Andreas Barner
Chairman of the Board of Managing Directors and Head of Corporate Board Division Pharma Research, Development and Medicine.
-
Prof. Dr Wolfram Carius
Head of Corporate Board Division Human Resources and Operations.
Shareholder's Committee
-
-
Images - Boehringer Ingelheim Photo Gallery
-
The international headquarters
The international headquarters: The Boehringer Ingelheim Center in Ingelheim/ Germany.
Die internationale Unternehmenszentrale: Das Boehringer Ingelheim Center in Ingelheim/ Rhein.
-
The international headquarters
The international headquarters: The Boehringer Ingelheim Center in Ingelheim/ Germany (aerial photo).
Die internationale Unternehmenszentrale: Das Boehringer Ingelheim Center in Ingelheim/ Rhein (Luftaufnahme).
-
Research and Development – Foundation for corporate success
Almost EUR 2.5 billion invested Boehringer Ingelheim in its research and development activities, amounting to EUR230 million more than in the previous year.
Knapp 2,5 Milliarden Euro hat Boehringer Ingelheim im vergangenen Jahr in seine Forschungs- und Entwicklungsaktivitäten investiert und somit 230 Millionen Euro mehr als im Vorjahr. -
The AAA Region showed itself to be the most dynamic market
Pharma research institute Kobe, Japan
Forschungszentrum am Standort Kobe, Japan
-
Animal Health business grows 51 percent
Model of the European research centre for animal vaccines in Hannover.
Modell des Europäischen Forschungszentrums für Tierimpfstoffe in Hannover.
-
Expanding global presence in biopharmaceuticals
Aerial view of Amgen's development and production site in Fremont, California, USA. The completed acquisition reinforces Boehringer Ingelheim's position as leading experts worldwide in developing and manufacturing biopharmaceuticals.
Luftbild des Standortes in Fremont (USA). Mit der Akquisition hat Boehringer Ingelheim seine Position als weltweit führender Experte für die Entwicklung und Herstellung von Biopharmazeutika.
-
Outlook 2011 – Start of a new growth phase
2010 Boehringer Ingelheim celebrated its 125th jubilee.
2010 feierte Boehringer Ingelheim sein 125-jähriges Jubiläum.
For further images please visit our Mediapool
-
